Prescient Therapeutics (PTX) is a clinical stage oncology company developing novel compounds that show great promise as potential new therapies to treat a range of solid and hematological cancers.

The Company’s novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Latest Announcements


11/01/2017
Investor Presentation January 2017
11/01/2017
PTX to present at Biotech Showcase 2017 in San Francisco
16/12/2016
Change of Registry Address
14/12/2016
First Patient Dosed on Phase 1b/2 AML Trial
08/12/2016
Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
30/11/2016
Results of Annual General Meeting